Clicky

Active Biotech AB(ACTI)

Description: Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.


Keywords: Medicine Biotechnology Cancer Clinical Medicine Pharmaceutical Products Immunotherapy Cancer Immunotherapy Multiple Myeloma Targeted Therapy Advanced Solid Tumors Immunosuppressants Uveitis Immunology Diseases

Home Page: www.activebiotech.com

Scheelevägen 22
Lund, 223 63
Sweden
Phone: 46 46 19 20 00


Officers

Name Title
Ms. Helen Tuvesson Ph.D. Pres & CEO
Mr. Hans Kolam Chief Financial Officer
Dr. Erik Vahtola Chief Medical Officer

Exchange: ST

Country: SE

Currency: Swedish krone (kr)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 5.6315
Price-to-Sales TTM: 29.7188
IPO Date:
Fiscal Year End: December
Full Time Employees: 9
Back to stocks